Ironwood Pharmaceuticals | IRWD - Ebitda


Ironwood Pharmaceuticals reported $81.81M in EBITDA for its fiscal quarter ending in September of 2025.





Ebitda Change Date
Acadia Pharmaceuticals USD -1.62M 21.94M Mar/2026
Agios Pharmaceuticals USD -108.66M 11.65M Mar/2026
Akebia Therapeutics USD 14.03M 17.19M Mar/2025
Almirall EUR 114.07M 60.37M Dec/2025
Alnylam Pharmaceuticals USD 245.34M 59.15M Jun/2026
Amarin USD 12.54M 28.57M Jun/2025
Ardelyx USD -29.77M 35.79M Mar/2026
Astellas Pharma JPY 235.24B 136.32B Jun/2026
AstraZeneca USD 5.16B 510M Jun/2026
Charles River Laboratories USD 229.8M 28.26M Mar/2026
Coherus Biosciences USD -43.33M 4.7M Sep/2025
Halozyme Therapeutics USD 219.57M 197.66M Mar/2026
Incyte USD 778.57M 410.6M Jun/2026
Ironwood Pharmaceuticals USD 81.81M 31.71M Sep/2025
Karyopharm Therapeutics USD -26.2M 1.83M Sep/2024
Lexicon Pharmaceuticals USD -12.04M 15.95M Sep/2025
MacroGenics USD -30.2M 52.15M Mar/2026
Moderna USD -1.26B 468M Mar/2026
Myriad Genetics USD 14.3M 4M Dec/2025
Pacira USD 48.67M 8.43M Jun/2026
PTC Therapeutics USD 61.98M 132.97M Mar/2026
Puma Biotechnology USD 729K 11.36M Jun/2024
Sarepta Therapeutics USD 375.48M 627.68M Mar/2026
Takeda JPY 364.46B 214.21B Jun/2026
Ultragenyx Pharmaceutical USD -155M 55.57M Mar/2026
Vanda Pharmaceuticals USD -8.31M 2.37M Dec/2024